Kyverna Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KYTX research report →
Range $25 – $25
Price Chart
About the company
Kyverna Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis.
- CEO
- Warner Biddle
- IPO
- 2024
- Employees
- 149
- HQ
- Emeryville, CA, US
Get TickerSpark's AI analysis on KYTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $283.23M
- P/E
- -1.62
- PEG
- -0.05
- P/S
- 0.00
- P/B
- 2.08
- EV/EBITDA
- -1.85
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -86.87%
- ROIC
- -98.49%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-169,827,000
- Net Income
- $-161,307,000-26.5%
- EPS
- $-3.64-9.3%
- OCF Growth
- -34.5%
- FCF Growth
- -32.0%
- Beta
- 2.13
- RSI (14)
- 30
No earnings-call transcripts are available for KYTX yet.
- Free Float
- 45.3%
- Shares Outstanding
- 63.22M
- Float Shares
- 28.63M
of shares held by institutions
128 13F filers
Buy/sell ratio 10.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Gordonmd Global Investments LP | 4.24M | 0 |
| Gilead Sciences, Inc. | 4.13M | 0 |
| Aigh Capital Management LLC | 3.65M | ▲ 854.20K |
| Blackrock, Inc. | 3.24M | ▲ 103.30K |
| Bain Capital Life Sciences Investors, LLC | 2.88M | ▼ 225.00K |
| Vanguard Capital Management LLC | 2.01M | ▲ 113.69K |
| Deerfield Management Company, L.P. | 2.00M | 0 |
| Vanguard Group Inc | 1.78M | ▲ 458.63K |
| State Street Corp | 1.20M | ▲ 221.02K |
| Price T Rowe Associates Inc | 1.19M | ▼ 369.26K |
| Geode Capital Management, LLC | 1.05M | ▲ 4.25K |
| Insight Holdings Group, LLC | 989.05K | 0 |
Held by 134 ETFs
Biggest fund positions in KYTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 27, 26 | CLARK IAN T | other | 5,093 |
| May 27, 26 | CLARK IAN T | other | 20,582 |
| May 27, 26 | Cohen Fred E | other | 5,093 |
| May 27, 26 | Cohen Fred E | other | 20,582 |
| May 27, 26 | SEIDENBERG BETH C | other | 5,093 |
| May 27, 26 | SEIDENBERG BETH C | other | 20,582 |
| May 27, 26 | Shaw Christi | other | 4,194 |
| May 27, 26 | Aktar Mert | other | 5,093 |
| May 27, 26 | Aktar Mert | other | 20,582 |
| May 18, 26 | Martini Gregory S. | other | 325,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KYTX coverage
Recent articles, reports, and earnings notes.
No research on KYTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KYTX report →